Realm Therapeutics (RLM) reports that it is making excellent progress advancing its proprietary therapeutic pipeline for inflammatory disease, with a cash reach to cover its Phase II programs in the first three indications. RLM’s Phase II study of PR013 in Allergic Conjunctivitis (AC) is progressing ahead of schedule with the expected top line readout shifting into Q118 (from Q2). As a reminder, RLM initiated the double blind, randomised, placebo controlled efficacy study of its topical solution using a modified Conjunctival Allergen Challenge Model Ora-CAC® in December measuring primary endpoints, ocular redness and itch.
15 Feb 2018
Funded pipeline progressing at speed
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Funded pipeline progressing at speed
Realm Therapeutics (RLM:LON) | 0 0 0.3% | Mkt Cap: 57.1m
- Published:
15 Feb 2018 -
Author:
Emma Ulker -
Pages:
2
Realm Therapeutics (RLM) reports that it is making excellent progress advancing its proprietary therapeutic pipeline for inflammatory disease, with a cash reach to cover its Phase II programs in the first three indications. RLM’s Phase II study of PR013 in Allergic Conjunctivitis (AC) is progressing ahead of schedule with the expected top line readout shifting into Q118 (from Q2). As a reminder, RLM initiated the double blind, randomised, placebo controlled efficacy study of its topical solution using a modified Conjunctival Allergen Challenge Model Ora-CAC® in December measuring primary endpoints, ocular redness and itch.